April 14, 2024

Mohammed Haneefa Nizamudeen

It’s been an fascinating few months for Lexicon Prescribed drugs (NASDAQ:LXRX) since I final wrote about this small, commercialization-stage biotech. Whereas the share value fell beneath $1 on a number of events, elevated optimism across the firm’s efforts to get